The federal 340B Drug Pricing Program has long been one of the most important and controversial funding streams for hospitals that serve vulnerable populations. Now, new transparency data from Minnesota is offering one of the clearest looks yet at how the program works in practice, and it is intensifying a national policy debate that could reshape hospital finances.
A February 2026 report from the Minnesota Department of Health found that hospitals and clinics participating in the 340B program generated at least $1.34 billion in net revenue in 2024, more than double the $630 million reported in 2023 after additional drug categories were included in the analysis.
The data is drawing attention in Washington and state capitals because Minnesota is currently the only state requiring hospitals to report detailed 340B revenue data, offering policymakers a rare window into a program that historically has had little transparency.
For hospital leaders, the findings underscore both the importance of the program and the increasing scrutiny it faces.
Large hospitals dominate the financial gains
The Minnesota report shows that large health systems captured the majority of 340B revenue. According to the state analysis, the state’s 23 general acute care hospitals generated more than $1.08 billion in net 340B revenue, accounting for more than 80 percent of the statewide total.
Overall, hospitals and clinics billed insurers and government programs about $3.04 billion for drugs purchased at steep discounts, while paying roughly $1.53 billion to acquire the drugs and another $165 million in operational costs, leaving the $1.34 billion net margin.
This dynamic reflects how the 340B program works. Hospitals purchase outpatient drugs at discounted prices but are reimbursed by insurers at standard rates. The difference generates revenue that hospitals often use to offset uncompensated care or support community programs.
However, critics argue the system has drifted from its original purpose of supporting safety-net providers. Safety-net clinics and federally qualified health centers generated only a small portion of the revenue in Minnesota’s report.
Why policymakers are paying attention
The findings arrive amid growing national scrutiny of the 340B program. Pharmaceutical companies, community oncology groups and some policymakers argue that large hospitals have increasingly used the program as a revenue engine rather than a targeted safety-net subsidy.
At the same time, hospitals counter that 340B funds help offset rising drug costs, support rural and underserved services and stabilize safety-net systems facing pressure from Medicaid reimbursement and labor costs.
The Minnesota data also highlights how little is known about how hospitals ultimately use the revenue. Current reporting requirements capture program revenue but do not track how hospitals spend those funds or how patients directly benefit, leaving a key policy question unresolved.
The national policy implications
Minnesota’s reporting law could serve as a blueprint for other states or Congress. Policymakers in multiple states are already exploring prescription drug transparency legislation and oversight of pharmacy supply chains.
If transparency efforts expand nationally, hospitals could face new reporting requirements and potential limits on how 340B savings are used.
Given the program’s size, the stakes are significant. National 340B drug purchases reached $81 billion in 2024, reflecting rapid growth across the health care system.
What hospital leaders should watch
Hospital executives should expect the debate over 340B to intensify in both Congress and state legislatures. As policymakers gain more visibility into program finances, new proposals could include transparency mandates, limits on contract pharmacies or reforms to eligibility rules.
For now, Minnesota’s experiment is providing the clearest signal yet: the era of limited oversight around 340B may be ending.
Key takeaways for hospital and health system leaders
• Expect increased transparency requirements. Minnesota’s reporting model may spread to other states or federal policy discussions.
• Prepare to demonstrate community benefit. Policymakers are increasingly asking how 340B revenue supports patient care and safety-net services.
• Monitor potential reforms to contract pharmacy arrangements. External pharmacy partnerships and administrative costs are a growing focus of scrutiny.
• Engage in the policy debate early. Health system leaders can shape reforms by clearly articulating how 340B funds support access, rural care and vulnerable populations.